Nov 2020

Nov 20, 2020 AGM Chairman address and CEO presentation

Nov 19, 2020 SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray

Oct 2020

Oct 30, 2020 Quarterly Cashflow and Activities Report

Oct 29, 2020 Completion of Placement and SPP raises $48.9M in total

Oct 21, 2020 Starpharma receives $5.7M R&D tax incentive refund

Oct 20, 2020 Shareholder Update October 2020

Oct 07, 2020 Share Purchase Plan offer document

Sep 2020

Sep 30, 2020 Starpharma completes oversubscribed A$45M placement - SPP to follow

Sep 30, 2020 Investor Presentation

Sep 25, 2020 VivaGel® BV secures TGA approval for prevention of BV

Sep 17, 2020 Starpharma to present at OTCQX Life Sciences Investor Forum

Sep 14, 2020 SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2

Sep 03, 2020 Starpharma awarded $1M MRFF funding for COVID-19 spray

Sep 01, 2020 SPL creates slow release soluble DEP® remdesivir nanoparticle

Aug 2020

Aug 27, 2020 Annual report and full year financial results

Aug 26, 2020 2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley

Aug 26, 2020 ABC News features Starpharma on ‘The Kohler Report’

Aug 26, 2020 Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19

Aug 25, 2020 SPL7013 nasal spray for COVID-19 – development update

Aug 17, 2020 Starpharma signs new DEP® partnership with Chase Sun

Jul 2020

Jul 30, 2020 Quarterly Cashflow and Activities Report

Jul 30, 2020 DEP® docetaxel and gemcitabine combination trial commences

Jul 27, 2020 AZD0466 trial opens MD Anderson Cancer Center as a site

Jul 09, 2020 New Australian site opening for DEP® trials

Jul 03, 2020 The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products

Jul 03, 2020 Pandemic a catalyst for boosting commercial outcomes, says Starpharma CEO

Jun 2020

Jun 29, 2020 DEP irinotecan boosts immuno-oncology in colon cancer models

Jun 25, 2020 The 7.30 report interviews Starpharma CEO Dr Jackie Fairley

Jun 25, 2020 Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report

Jun 23, 2020 Multiple DEP® products showcased at AACR 2020

Jun 19, 2020 SBS speaks to Starpharma CEO Dr Jackie Fairley on female representation in business

Jun 19, 2020 Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Jun 18, 2020 Starpharma to present at OTCQX Virtual Investor Conference

Jun 17, 2020 DEP® lutetium effective in human prostate cancer model

Jun 16, 2020 VivaGel® BV launched in central and eastern European countries

May 2020

May 18, 2020 Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)

May 14, 2020 Shareholder Update May 2020

May 11, 2020 Starpharma CEO Dr Jackie Fairley on ausbiz

May 07, 2020 DEP® irinotecan phase 2 commences after positive phase 1 results

May 05, 2020 Starpharma presents at Macquarie Australia Conference

Apr 2020

Apr 22, 2020 Australia’s biotech sector tests multiple agents to fight COVID-19

Apr 16, 2020 Condom gel compound proves effective against COVID-19

Apr 16, 2020 Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013

Apr 16, 2020 Starpharma’s SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)

Apr 15, 2020 SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)

Apr 07, 2020 Quarterly Cashflow and Activity Report

Mar 2020

Mar 30, 2020 COVID-19 measures

Mar 04, 2020 Okamoto licenses VivaGel® antiviral condom in Asian countries

Mar 02, 2020 Starpharma appoints David McIntyre and Appendix 3X

Feb 2020

Feb 24, 2020 Interim Report and Half-Year Financial Results

Feb 13, 2020 Starpharma collects milestone payment from AstraZeneca

Feb 13, 2020 Starpharma share price charges higher on product launch news

Feb 13, 2020 VivaGel BV launched in Asia

Feb 12, 2020 David McIntyre appointed as non-executive director

Feb 11, 2020 Starpharma receives US$3M milestone from AstraZeneca

Jan 2020

Jan 30, 2020 Shareholder Update January 2020

Jan 29, 2020 Quarterly Cashflow Report